Sanofi Consumer Healthcare has been listed on the BSE and NSE after its demerger from Sanofi India. Approved by the National Company Law Tribunal, this move aligns with Sanofi's global strategy.

Sanofi Consumer Healthcare India Limited has been listed on the BSE and National Stock Exchange (NSE). SCHIL’s demerger from Sanofi India Limited, executed under the Scheme of Arrangement, was ...

In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.

Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...

While it’s put more em­pha­sis on be­com­ing an “im­munol­o­gy pow­er­house” in re­cent quar­ters, Sanofi still shows signs of in­ter­est in on­col­o­gy.

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

Sanofi is following several of its big pharma industry peers into radiopharmaceuticals, striking a deal for a clinical-stage therapy now in discussion for a regulatory submission as a treatment ...

PARIS & HOUSTON, September 12, 2024--(BUSINESS WIRE)--Regulatory News: As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an ...

NEW YORK – With a new licensing deal announced Thursday, Sanofi is the latest drugmaker to join the burgeoning radiopharmaceutical market. The Paris-based firm inked a deal with Houston-based ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. On the same day the companies unveiled positive data from a study in chronic spontaneous urticaria (CSU) and a ...

Sanofi’s Modulus plant has been established with funding of €500m. Credit: HJBC/Shutterstock. Sanofi has announced the inauguration of its new modular vaccine and biomedicine production unit, Modulus, ...

Quanto a Suzano (SUZB3), o banco manteve sua recomendação de compra, mas também elevou o preço-alvo para ação de R$ 77,50 para R$ 80,50 para 2025, potencial de 48%. Nesta terça-feira (10), as ações da ...